Articles by Gerald N. Rogan, MD - Pharmaceutical Executive

ADVERTISEMENT

Articles by Gerald N. Rogan, MD

Back Page: Diagnostic Dilemma

Nov 1, 2004

Medicare and other payers should consider R&D costs when establishing prices for biotechnology tests-or compromise the industry's future ability to develop targeted therapies.

ADVERTISEMENT

Click here